APOBEC3B

Across TCGA pan-cancer cohorts, APOBEC3B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APOBEC3B data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher APOBEC3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APOBEC3B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC, HNSC, and GBM are the cancer types where APOBEC3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.942	1.000	.021	7	view →
HNSC	OS	Quartile	All	0.712	0.928	.027	4	view →
GBM	DFS	Tertile	All	0.650	0.264	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

APOBEC3B–LSCC (DFS)

Open the LSCC breakdown →